Testing effectiveness (Phase 2)Looking for participantsNCT06797297
What this trial is testing
Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Who this might be right for
Melanoma
Innovent Biologics (Suzhou) Co. Ltd. 180